{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-034674","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.566689+00:00","generated_at":"2026-06-04T16:40:29.212844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024","bullets":["FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).","Product gross margin improved to 72% from 70%; expects 75-80% in 2024.","STAR-T trial selected for Breakout Presentation at AATS (April 2024); FDA/Health Canada submission planned for H2 2024.","Ended 2023 with $15.6M cash; cost cuts include 15% RIF; cash runway into Q4 2024.","Entered India partnership with Eris Lifesciences; plan to launch PuriFi pump in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-034674","json":"https://secwatch.observer/filing/0001104659-24-034674.json","markdown":"https://secwatch.observer/filing/0001104659-24-034674.md","text":"https://secwatch.observer/filing/0001104659-24-034674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/tm248917d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T16:40:29.212844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13cea5277e1b89a7286977552d57b71a9bac3566","claim":"Cytosorbents Corp reported quarter and year ended December 31, 2023 results: revenue $36.3 million.","evidence_excerpt":"quarter and year ended December 31, 2023 and provides its 2024 outlook. Full Year 2023 Financial Results · 2023 Total Revenue, which includes Product Sales and Grant Income, was $36.3 million versus $34.7 million in 2022, an increase of approximately $1.7 million or 5% · Total product sales were $31.1 million in 2023 versus $29.4 million in 2022, an increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$36.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}